Specialty
Intensive Care Medicine
Pediatrics & Neonatology
Occupational Medicine
Emergency Medicine
Anesthesiology
Pulmonology
Internal Medicine
Radiology
Nephrology
Allergy and Immunology
Sports Medicine
Nutrition
Neurosurgery
Cardiovascular medicine
Surgery
Gynecology
Companies
Departments
Cardiac Rehabilitation
Imaging Department
OB/GYN Department
Dialysis Department
HR Heart Rate
SD Stroke Distance
MD Minute Distance
FTc Flow Time Corrected
PV Peak Velocity
MA Mean Acceleration
Derived Values: User inputs – Patient Sex, Age, Height, Weight
CO Cardiac Output
CI Cardiac Index
SV Stroke Volume
SVI Stroke Volume Index
BMI Body Mass Index
BSA Body Surface Area
User inputs – Mean Arterial Pressure (MAP) and Central Venous Pressure (CVP)
SVR Systemic Vascular Resistance
SVRI Systemic Vascular Resistance Index
User inputs_Oxygen saturation and Haemoglobin
DO2 Delivered Oxygen
DO2I Delivered Oxygen Index
Hemodynamic Monitoring
Now succeeded by ODM+, ODM (also known as CardioQ-ODM) enables hospital clinicians to deliver accurate, real-time, guided Hemodynamic Management. It is an important aid in avoiding the dangers of reduced oxygen delivery.
The ODM monitor is highly responsive in tracking changes in Stroke Volume and Cardiac Output during surgical intervention and in the critical care setting. Only esophageal Doppler has been shown to have the precision to drive the 10% Stroke Volume Optimization algorithm, widely acknowledged as the basis for hemodynamic management.
Uniquely, esophageal Doppler monitoring (ODM) directly measures blood flow in the central circulation. It is highly sensitive to changes in flow and measures them immediately and accurately. The system offers a high degree of precision (low repeatability error), which allows it to recognize the small changes in Stroke Volume, which is the basis of published Stroke Volume Optimization protocols.
Deltex Medical is a British manufacturer of Fluid Management devices, which include the ODM+ hemodynamic monitoring systems. From its head office and manufacturing base in Chichester, West Sussex, the company now has subsidiaries in the USA, Canada and Spain.
Deltex’s mission is to benefit patients and healthcare providers by making esophageal Doppler monitoring (ODM) the standard of care wherever possible. We’re passionate about this because the evidence tells us that use of ODM to guide fluid and drug administration results in better outcomes. Better outcomes for patient, clinician and healthcare provider.
The principle is that by accurately monitoring and managing a patient’s hemodynamic status, the risk of complications is minimized. This means longer life, shorter hospital stay and reduced cost of care.
Deltex’s robust evidence base has been established over many years. It is a compelling story of clinical benefit and cost-effectiveness that is helping the company to achieve system-wide adoption of this unique medical technology.
We’re working hard on our mission across the world. There are already over 3,000 ODM systems in use in hospitals globally with distribution in over 30 countries.
Deltex Medical has been awarded a NICE recommendation for the CardioQ-ODM. ODM Fluid Management is one of the six High Impact Innovations, based on comprehensive evidence which proves that ODM Fluid Management can reduce postoperative complications and reduce length of hospital stay.